CellSource Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
CellSource Co., Ltd. carries a market capitalization of 6.53B, placing it among publicly traded companies globally. Its enterprise value stands at 26.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.53B |
| Enterprise Value | 26.26B |
Share Statistics
CellSource Co., Ltd. currently has 19.81M shares outstanding.
| Shares Outstanding | 19.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CellSource Co., Ltd. trades at a trailing price-to-earnings ratio of 37.95. The price-to-sales ratio is 6.76, and the price-to-book ratio stands at 6.55.
| PE Ratio | 37.95 |
| PS Ratio | 6.76 |
| PB Ratio | 6.55 |
| P/TBV Ratio | 5.11 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, CellSource Co., Ltd. trades at an EV/EBITDA multiple of 31.12 and an EV/FCF ratio of 29,990.77. The EV/Sales ratio of 5.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 31.12 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.75 |
| EV / EBITDA | 31.12 |
| EV / EBIT | 31.12 |
| EV / FCF | 29,990.77 |
Financial Position
CellSource Co., Ltd. maintains a current ratio of 9.53, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.53 |
| Quick Ratio | 8.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 767.64 |
Financial Efficiency
CellSource Co., Ltd. posts a return on equity of 19.68 and a return on invested capital of 12.52.
| Return on Equity (ROE) | 19.68 |
| Return on Assets (ROA) | 13.91 |
| Return on Invested Capital (ROIC) | 12.52 |
| Return on Capital Employed (ROCE) | 19.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.43 |
Taxes
Over the trailing twelve months, CellSource Co., Ltd. has paid 207.59M in income taxes, reflecting an effective tax rate of 20.34.
| Income Tax | 207.59M |
| Effective Tax Rate | 20.34 |
Stock Price Statistics
CellSource Co., Ltd.'s stock has declined approximately -50.67466% over the past 52 weeks. The 50-day moving average sits at 336.26, while the 200-day moving average is 418.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.67466% |
| 50-Day Moving Average | 336.26 |
| 200-Day Moving Average | 418.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CellSource Co., Ltd. generated 4.57B in revenue and converted that into 813.06M in net income, yielding earnings per share of 40.85. EBITDA reached 843.64M, while operating income came in at 843.64M.
| Revenue | 4.57B |
| Gross Profit | 3.07B |
| Operating Income | 843.64M |
| Pretax Income | 1.02B |
| Net Income | 813.06M |
| EBITDA | 843.64M |
| EBIT | 843.64M |
| Earnings Per Share (EPS) | 40.85 |
Balance Sheet
Total book value stands at 4.71B, with working capital of 4.80B providing operational flexibility.
| Cash & Cash Equivalents | 4.60B |
| Total Debt | N/A |
| Net Debt | -4.60B |
| Equity (Book Value) | 4.71B |
| Book Value Per Share | 237.91 |
| Working Capital | 4.80B |
Margins
CellSource Co., Ltd. operates with a gross margin of 67.15, reflecting its pricing power and cost economics. The operating margin of 18.47 and net profit margin of 17.80 provide insight into operational efficiency.
| Gross Margin | 67.15 |
| Operating Margin | 18.47 |
| Pretax Margin | 22.35 |
| Profit Margin | 17.80 |
| EBITDA Margin | 18.47 |
Stock Splits
CellSource Co., Ltd.'s most recent stock split took place on October 28, 2021 with a 1:3 split ratio.
| Last Split Date | 10/28/2021 |
| Split Ratio | 1:3 |
Scores
CellSource Co., Ltd. posts an Altman Z-Score of 26.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 26.34 |